Genomic/Proteomic PTB Network: UAB Clinical Core Center

早产仍然是围产儿发病率和死亡率的主要原因，即早产率 早产的风险持续增加，预防早产的有效干预措施仍然是虚幻的。调查人员在 我们机构的妇女健康研究中心在以下方面提供了强大的临床研究领导 这个地区已经有25年的历史了。我们已经成功地获得了数百万美元的联邦资金来进行临床 旨在提高我们对早产病理生理学的理解的研究，以及测试 前瞻性随机试验中的许多潜在干预措施。我们团队的生产力已经导致了 在早产及其预防方面发表了数百份出版物。我们在高性能方面的卓越表现- 高质量、精心设计的临床试验广为人知。与这一应用程序密切相关的是我们的独特优势和 成功进行多中心试验，并在研究网络中发挥领导作用，包括 NICHD母胎医学单位网络，我们已参与该网络近15年 好几年了。事实上，在该网络的14个中心中，UAB的整体表现在 最新的成员机构客观排名。因此，我们认为我们特别好- 定位，不仅要有效参与，而且要作为临床核心中心在 建议的基因组和蛋白质网络。在本申请中，我们将详细描述我们非常 成功的临床研究设施和基础设施。我们还将强调我们有充分记录的 优势包括患者收益和留存、高质量数据采集和录入、快速提升到 启动新的试验、遵守协议、分析和发布工作效率以及协作成功 NICHD MFMU网络中的协议开发和实现 拟议的新网络就是基于该网络的。我们相信，我们对这个项目的热情和承诺 这将是显而易见的，我们相信我们的资格将非常有竞争力被考虑。

Preterm birth remains the leading cause of perinatal morbidity and mortality, the rate of preterm birth continues to increase, and effective interventions to prevent preterm birth remain illusive. Investigators in the Center for Research in Women's Health at our institution have provided strong clinical research leadership in this area for 25 years. We have successfully acquired millions of dollars in federal funding to conduct clinical studies designed to improve our understanding of the pathophysiology of preterm birth as well as to test many potential interventions in prospective randomized trials. The productivity of our group has resulted in hundreds of publications in the area of preterm birth and its prevention. Our excellence in performing high- quality well-designed clinical trials is widely known. Germane to this application is our particular strength and success in performing multi-center trials and providing a leadership role in research networks including the NICHD Maternal-Fetal Medicine Units Network in which we have been a participating institution for nearly 15 years. Indeed, UAB was ranked first in overall performance among the 14 centers in this Network in the most recent objective ranking of member institutions. Thus, we believe that we are particularly well- positioned, not only to effectively participate, but also to provide leadership as a Clinical Core Center in the proposed Genomic and Proteomic Network. In this application, we will describe in detail our extremely successful clinical research facilities and infrastructure. We will also emphasize our well-documented strengths including patient accrual and retention, high-quality data acquisition and entry, rapid ramp-up to initiate new trials, protocol adherence, analysis and publication productivity, and collaborative success in protocol development and implementation in the NICHD MFMU Network which appears to be a model upon which the proposed new network is based. We believe that our enthusiasm and commitment to this project will be evident and we believe that our qualifications will be very competative for consideration.